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Purpose. Assessing the role of breast MRI compared to galactography in patients with unilateral bloody or serous-bloody nipple
discharge. Materials and Methods. Retrospective study including 53 unilateral discharge patients who performed galactography
and MRI. We evaluated the capability of both techniques in identifying pathology and distinguishing between nonmalignant and
malignant lesions. Lesions BIRADS 1/2 underwent follow-up, while the histological examination after surgery has been the gold
standard to assess pathology in lesions BIRADS 3/4/5.The ROC analysis was used to test diagnostic MRI and galactography ability.
Results. After surgery and follow-up, 8 patients had no disease (15%), 23 papilloma (43%), 11 papillomatosis (21%), 5 ductal cancer
in situ (10%), and 6 papillary carcinoma (11%) diagnoses. Both techniques presented 100% specificity; MRI sensitivity was 98%
versus 49% of galactography. Considering MRI, we found a statistical association between mass enhancement and papilloma (𝑃 <
0.001; AUC 0.957; CI 0.888–1.025), ductal enhancement and papillomatosis (𝑃 < 0.001; AUC 0.790; CI 0.623–0.958), segmental
enhancement and ductal cancer in situ (𝑃 = 0.007; AUC 0.750; CI 0.429–1.071), and linear enhancement and papillary cancer
(𝑃 = 0.011). Conclusions. MRI is a valid tool to detect ductal pathologies in patients with suspicious bloody or serous-bloody
discharge showing higher sensitivity and specificity compared to galactography.
1. Introduction
Nipple discharge represents about 7–10% of breast symptoms
and it is the third most common complaint after pain and
breast masses [1–4]. It is usually caused by benign conditions,
but occasionally it indicates a serious medical problem,
especially when it is spontaneous and bloody/serous-bloody
and is not associated with physiological conditions, such as
pregnancy or breastfeeding [5].
The most common causes are some benign breast lesions
[6], such as solitary intraductal papilloma and papillomatosis
followed, in a small percentage of cases (between 5% and
21%), by malignant lesions, such as papillary carcinoma, duc-
tal cancer in situ (DCIS), and invasive ductal carcinoma [7, 8].
The diagnostic patients management requires a complete
clinical history, physical examination, cytological exam, and
radiological exams [9]. Unfortunately, the cytological exam
is not always diagnostic. Mammography and sonography
are considered the first imaging methods performed as
standard of care in the nipple discharge diagnostic evaluation.
Nonetheless, bothmethodsmay present some limitations and
difficulties in evaluating intraductal lesions [10, 11].
For a long time, galactography has been considered the
gold standard to assess nipple discharge [12, 13]. It directly
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Figure 1: Image findings of (a) ductal ectasia, (b) filling stop, (c) filling defect, and (d) ductal distortion.
shows the secreting duct, which is cannulated and opacified
through the contrast medium injection [14]. It is a safe and
economical method, in most cases easily available. However,
it does not always display specific findings, so it could be
difficult to build a differential diagnosis between benign and
malignant ductal breast diseases [15, 16].
Moreover, it could be difficult to cannulate the duct,
especially in patients with intermittent discharge or nipple
retraction. Another important detail is the ionizing radiation
use, chiefly in up to 35 years old patients [17].
Magnetic resonance imaging (MRI) is a high sensitivity
technique in detecting breast diseases such as invasive breast
cancer (68–100%) and DCIS (77–96%) [18, 19].
Several studies have been conducted to evaluate the
potentialMRI diagnostic role in ductal pathologies diagnosis,
but few researchers have made a comparison between MRI
and galactography [9, 20–22].
The aim of the study is the comparison between galactog-
raphy and MRI in patients with bloody/serous-bloody uni-
lateral nipple discharge, in order to evaluate their sensitivity,
specificity, and accuracy for the right differential diagnosis
between benign and malignant diseases.
2. Materials and Methods
2.1. Members and Inclusion Criteria. In our study, we per-
formed a retrospective analysis. We extrapolated patients
presenting bloody or serous-bloody nipple discharge from
our radiological database, which collected 1700 consecutive
breast MRIs. Fifty-three female patients, aged between 28
and 65 years of age (average age 42 years old), respected our
inclusion criteria.They presented unilateral bloody or serous-
bloody nipple discharge and performed both galactography
and MRI exams at our Radiological Sciences Department.
The time elapsed between the two examswas twoweeksmaxi-
mum.All patients presenting lesions classified as BIRADS 1 or
BIRADS 2 underwent follow-up, performed with mammog-
raphy, ultrasound, or cytology. The average follow-up was
18 months. The histological examination has been the gold
standard to assess the kind of pathology in lesions classified
as BIRADS 3, BIRADS 4, and BIRADS 5.
2.2. Galactography. Galactography was performed cannu-
lating the secretory duct with a blunt dedicated cannula,
through which was injected a nonionic iodinated contrast
agent (iopamidol 300) up to a maximum of 1–1.5mL. After
the cannula removal, radiographs on craniocaudal andmedi-
olateral oblique projections have been acquired with a digital
mammography system (Trade Art 2000, Planmed Nuance
Aprilia, Rome).
Findings were classified according to the Gregl scheme
[23] into the following groups as showed in Figure 1:
(1) technically inadequate investigation,
(2) normal findings,




2.3. Magnetic Resonance Imaging. Magnetic resonance imag-
ing (MRI) has been performed using a 1.5 Tesla magnet
(Magnetom Vision, Avanto Siemens Medical System, Erlan-
gen, Germany; gradients 25mT/m2; slew rate 800 T/m/s; rise
time 400 𝜇s) with dual coil dedicated to the breast study
(4-Channel BI Breast Coil). In premenopausal patients we
performed the examination between the 7th and the 14th
menstrual cycle day.
The protocol includes sequences obtained before contrast
medium administration: T2-STIR weighted sequences on the
axial plane (TR 5320/TE 58ms; FOV read 300; FOV phase
100; slice thickness 3.5mm without gap, length 5min); 3D
Flash NFS T1-weighted sequences on the axial plane (TR
7.73/TE 4.76ms; Flip angle 25, FOV read 320; FOV phase
100; thickness 1mm; length 1min and 37 s); and T1 Flash 3D
FS on the sagittal plane (TR/TE 8/5ms; FOV read 330; FOV
phase 100; slice thickness 1mm; length: 1min and 50 s) on the
secretory breast.
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The image acquisition on axial and sagittal planes has
allowed three-dimensional ductal tree visualization.
Then we used 3D gradient recalled echo (GRE) fat
saturationT1-weighted sequences on axial and sagittal planes,
acquiring a single scan before (length 2min and 53 sec) and
four consecutive scans (delay of 10 sec from basal scan) after
contrast medium administration length of each scan (2min
and 53 sec without delay). Total length of the exam is about
20 minutes.
The contrast medium introduction was performed using
an automatic injector administrating gadobutrol at a dose
of 0.1mmol per body weight kilogram with a rate of 2mL/s
together with 10mL of saline bolus.
T2-STIR sequences were used to obtain information
about breast morphology and structure (presence of fatty,
fibrous, and glandular tissue) and to evaluate the ductal
system. Ductal ectasia appeared in the shape of single or
multiple tubular images thanks to high signal intensity onT2-
weighted images.
Flash 3D fat saturation (FS) precontrast T1-weighted
images were analyzed for intraluminal fluid content charac-
terization, identifying the presence of high signal intensity,
such as blood or proteinaceous material.
To evaluate any enhancing areas we executed T1-weighted
sequences after contrast medium administration. In particu-
lar, we considered parameters like morphology and the type
of enhancement. For each enhancing lesion, we classified the
type of enhancement according to the BIRADS lexicon as
mass-like or non-mass-like (linear, ductal, segmental, and
regional).
Two radiologists of 15- and 5-year experience in breast
imaging blinded to the histological examination indepen-
dently reviewed MRI and galactographic exams.
2.4. Histopathology. Thirty-three patients underwent core-
needle biopsy (CNB) procedure. CNB has been performed
under ultrasound (US) guidance using a 14 Gauge automated
biopsy gun (Bard, Magnum Biopsy Instrument, Covington,
Georgia, USA) or a semiautomated biopsy gun (PRECISA,
Hospital Service, Aprilia, Italy). We obtained a minimum of
three samples for each biopsy. Eleven patients, presenting
multiple lesions in the context of the duct, directly underwent
surgery because of the slight risk of association between
papilloma and papillomatosis with breast cancer [24].
2.5. Statistical Analysis. Diagnostic sensitivity, specificity, and
positive and negative predictive value (PPV and NPV) for
both modalities were assessed.
TheROCanalysis tested the galactography andMRI diag-
nostic ability separately. Subsequently, they were compared to
histological analysis.
The statistical ROC analysis method is commonly used
to evaluate the efficacy of a single diagnostic modality. The
combined use of different complementary modalities makes
it necessary to evaluate the single contribution provided by
each of these modalities.
The area under the curve (AUC) of each diagnostic
modality was calculated and results were presented with 95%
of confidence intervals (CI 95%).
We performed Fisher’s exact probability test for univari-
ate analyses and, where possible, the 𝜒2 test with continuity
correction.
Statistical analysis was performed using SPSS 19.0 for
Windows and statistical significance was set at 𝑃 < 0.05.
3. Results
Histologic examination performed after surgery or CNB
showed that our sample was composed by 23 patients with
papillomas (43%), 11 with papillomatosis, (21%) 5 with DCIS
(10%), and 6 with papillary carcinomas (11%). Eight patients
(15%) without lesions both on galactography and on MRI
follow-up were classified as negative.
Considering the benign lesions, 2/23 cases with histolog-
ical diagnosis of papilloma were classified as G2 and 13/23 as
G3 through galactography according to Gregl classification.
These cases were considered as false negative (FN), G2
being a normal finding and G3, the condition of ductal
ectasia, a nonspecific finding. In the remaining eight cases
galactography was diagnostic, while MRI correctly identified
all the lesions (19/23 cases of mass-like enhancement, 2/23
cases of ductal enhancement, and 2/23 cases of the association
of mass-like and ductal enhancement). In 10 cases, even
with precontrast sequences we observed solid intraductal
formation.
Concerning papillomatosis, galactography correctly
identified the pathology in 5/11 cases, while it classified as
G3 (nonspecific findings) 6/11 cases of papillomatosis, which
were considered as FN. MRI was diagnostic in all cases,
showing 8 ductal and 3 regional enhancements. Moreover,
through precontrast sequences, we identified three cystic
ductal ectasia cases and two solid intraductal mass cases.
Concerning malignant disease, 6 patients had papillary
carcinoma; MRI correctly identified all of them (2 regional
enhancement cases, 4 ductal enhancement cases, 2 simple
and 2 branched enhancement, each one of them was associ-
atedwith ductal ectasia), while galactography showed one FN
case.
Considering DCIS, galactography and MRI correctly
identified 4/5 cases; one of them was classified as G2 through
galactography and showed no contrast medium uptake
through MRI, so it was considered as FN.
Overall, we did not observe false positive (FP) cases; MRI
showed one FN case (one case of DCIS) and galactography
23 FN cases (15 cases of papilloma, 1 case of papillary cancer,
1 case of DCIS, and 6 cases of papillomatosis). Galactography
showed an overall sensitivity of 48.89%, a specificity of 100%,
a PPVof 100%, and aNPVof 25.81% in detecting the presence
of ductal pathologies, while forMRI sensitivity was of 97.78%,
specificity of 100%, PPV of 88.89%, and NPV of 100%.
Once we evaluated capability of both methods to identify
the ductal pathology, we tried to establishwhether there was a
specific radiological sign associated with a specific histologic
subtype, in order to perform a correct differential diagnosis
between benign and malignant lesions.
Considering galactography, the univariate analysis
showed a statistically significant association (𝑃 < 0.001)
between ductal distortion (G6) and papillary cancer and
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Table 1: Univariate analysis showing galactography compared to histological finding.
Histology G2 G3 G4 G5 G6
𝑛 (%), 𝑃 𝑛 (%), 𝑃 𝑛 (%), 𝑃 𝑛 (%), 𝑃 𝑛 (%), 𝑃
No pathology 7 (63.7), 0.001 2 (5.9), 0.019 0, 0.175 0, 0.174 0, 0.578
Papilloma 2 (18.2), 0.089 18 (52.9), 0.113∗ 7 (58.3), 0.392∗ 6 (50), 0.899∗ 0, 0.016
Papillary cancer 1 (9.1), 1 4 (11.8), 1 1 (8.3), 1 0, 0.316 5 (71.4),<0.001
DCIS 1 (9.1), 1 3 (8.8), 1 0, 0.577 3 (25), 0.034 1 (14.3), 0.530
Papillomatosis 0, 0.94 7 (20.6), 1 4 (33.3), 0.244 3 (25), 0.701 1 (14.3), 1
∗𝜒





















































Figure 2: The ROC curves show an association between (a) papillary cancer and G6 on galactography (AUC 0.894; CI 0.715–1.074) and (b)
between DCIS and G5 (AUC 0.790; CI 0.534−1.046).
between filling stop (G5) and DCIS (𝑃 = 0.034) (Table 1).
35/53 cases presented ductal ectasia (G3), thus resulting in
a nonspecific finding. The filling defect (G4) has been the
most frequent finding in papilloma cases (7/23), but these
data were not significant.
The ROC analysis allowed us to verify our data, demon-
strating an association between G6 at galactography and
papillary cancer (AUC: 0.894; CI 0.715–1.074) and between
G5 and DCIS (AUC: 0.790; CI 0.534−1.046), as shown in
Figures 2(a) and 2(b).
In addition, galactography showed an overall trend to
correctly identify malignant lesions, but no significant asso-
ciation has been found between one Gregl scale radiological
sign and histological benign lesions. Considering MRI, we
found a statistically significant association between mass
enhancement and the presence of papilloma (𝑃 < 0.001),
between ductal enhancement andpapillomatosis (𝑃 < 0.001),
between segmental enhancement and DCIS (𝑃 = 0.007),
and between linear enhancement and papillary cancer (𝑃 =
0.011) as shown in Table 2.
ROC analysis confirmed the association between mass
enhancement and papilloma (AUC 0.957; CI 0.888−1.025),
segmental enhancement and DCIS (AUC 0.750; CI 0.429−
1.071), and ductal enhancement and papillomatosis (AUC
0.790; CI 0.623–0.958), as shown in Figures 3(a) and 3(b).
4. Discussion
Nipple discharge is a relatively common symptom in the
clinical practice and in most cases it is related to a benign
condition. However, if it is especially spontaneous and shows
a bloody/serous-bloody content, it requires a careful analysis
to exclude malignant diseases. Therefore, it is important not
only to identify the presence of disease but also to discrim-
inate the causes of the discharge, differentiating malignant
from benign lesions.
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Table 2: Univariate analysis showing MRI compared to histological finding.
Histology Mass Ductal (linear) Ductal (branched) Regional Segmental
𝑛 (%), 𝑃 𝑛 (%), 𝑃 𝑛 (%), 𝑃 𝑛 (%), 𝑃 𝑛 (%), 𝑃
Negative 0, 0.15 0, 1 0, 0.093 0, 0.573 0, 1
Papilloma 21 (95.5),<0.001∗ 0, 0.499 4 (28.6), 0.225 0, 0.028 0, 0.499
Papillary cancer 0, 0.035 2 (100), 0.011 2 (14.3), 0.649 2 (33.3), 0.136 0, 1
DCIS 1 (4.5), 0.389 0, 1 0, 0.309 1 (16.7), 0.397 2 (100), 0.007
Papillomatosis 0, 0.001 0, 1 8 (57.1),<0.001 3 (50), 0.101 0, 1
∗𝜒





















































Figure 3: ROC analysis confirms the association between (a) mass enhancement and papilloma (AUC 0.957; CI 0.888−1.025) and (b)
segmental enhancement and DCIS (AUC 0.750; CI 0.429−1.071).
In this study we attempted to evaluate the role of the
two imaging methods, galactography and MRI, in a patients’
sample presenting a specific symptom, ductal bloody and
serous-bloody discharge.
We found a statistically significant difference in over-
all sensitivity between the two methods. Particularly, MRI
showed higher value of sensitivity (97.78% versus 48.89%
galactography sensitivity) to identify ductal pathologies,
while for both the methods specificity was 100%. In our
analysis, the galactography sensitivity rates were lower than
the others previously reported [25, 26]. This is probably due
to the fact that in these previous studies the ductal ectasia
(DE) condition had been considered as a pathologic finding.
However, DE is also very common in asymptomatic patients,
who never presented nipple discharge. In our sample, ductal
ectasia has been found in 49/53 patients and particularly in
all patients without disease. Therefore, we considered G3 as a
pathological finding only if it is associated with other ductal
anomaly signs.
Considering the capability tomake a correct disease inter-
pretation, even if the two methods specificity was the same
(100%), MRI provided imaging findings, which allowed us
to understand the underlying disease causing the pathologic
discharge. In fact, we could see not only the pathological
duct or ducts, using T2 and T1 precontrast sequences, but
also the surrounding parenchyma enhancement. This aspect
gave the overall evaluation of disease, justifying theMRI high
sensitivity.
The breast MRI role in evaluating nipple discharge is
still controversial [21, 22, 27]. Current indication for breast
MRI, according to EUSOBI guidelines, does not include
the evaluation of patients presenting with nipple discharge,







Figure 4: 53-year-old patient presenting serous-bloody nipple discharge. Craniocaudal (a) and mediolateral oblique (b) mammographic
images show the filling stop few millimeters distant from the nipple of the cannulated duct, imaging finding suggestive of papilloma. MRI
image (T1-weighted 3D flash acquired in the axial plane) shows a mass intraductal enhancement in the retroareolar area (c) with round and
sharp margins, indicative of a benign proliferation of the ductal epithelium (papilloma). Histology later confirmed the papilloma diagnosis.
although the potential role ofMRI has already been evaluated
in previous studies [28].
Several authors have carried out studies on the role of
MRI contrast galactography cannulating and using intraduc-
tal contrast materials to enhance the secreting ducts. In 1997
Yoshimoto et al. [29] performed MRI contrast galactography
after galactography in a patient, and the contrast material
was injected both intravenously and into the discharging
duct. Yu¨cesoy et al. [30] compared conventional galacto-
graphy with MRI contrast galactography in a prospective
study performed with 16 patients showing 81% concordance
between the two methods; their data suggest that MRI con-
trast galactography could be used as an alternative imaging
modality for the pathologic nipple discharge diagnosis.
To the best of our knowledge, our study involved the
largest sample in which all participants performed both
galactography and conventional breast MRI using a breast
dedicated coil without cannulating the secreting duct.
We evaluated if breastMRI could be used as an alternative
imaging method in this specific group of patients, especially
to express a differential diagnosis between benign andmalig-
nant lesions.
Galactography is a widely used and accepted diagnostic
tool for visualizing and localizing ductal pathologies but
frequently yields nonspecific findings, such as ductal ectasia,
filling defects, and duct wall irregularities, which are ductal
disease signs but does not always allow identification of the
discharge cause. Thus, a positive study does not differentiate
between malignant and benign discharge causes, and a
negative study does not exclude an underlying carcinoma (or
high-risk lesion). In our study theNPV for galactographywas
only 25.81% versus 100% for MRI [15, 29].
In addition, cannulation is possible only if the duct is
discharging during the investigation time.
If we consider benign diseases, in our sample galactogra-
phy did not correctly identify 15 cases of papilloma and six
of papillomatosis. On ductography, an intraductal papilloma
appears as a round or lobulated filling defect, with a localized
smooth surface, in a dilated duct (Figures 4(a) and 4(b)).
The lesion typically arises from a single major duct in the
subareolar region [31, 32]. To our experience, most lesions
had small sizes (diameter less than 8mm) non determining
a complete duct obstruction. In addition, some lesions had
a peripheral location; therefore, we could not observe direct
radiological signs on galactography, which in most cases
revealed only ductal ectasia. Instead, all benign lesions were
correctly identified through MRI. Particularly, papillomas
were detected when galactography was unsuccessful, appear-
ing as an enhancing mass in a dilated duct, as shown in
Figure 4(c).
We found a statistically significant association between
papillomatosis (Figures 5(a), 5(b), and 5(c)) and ductal
enhancement. Ductal irregularity, encasement, distortion,
obstruction, or irregular filling defects are conventional
galactography findings suggestive of malignancy. We found a
statistically significant association between ductal distortion
(G6) and papillary cancer and between “stop” (G5) andDCIS.
Galactography was able to discriminate malignant lesions; in
two FN cases, it revealed only amodest ductal ectasia without
filling defects or wall irregularities (Figures 6(a) and 6(b)).
In our study, MRI correctly identified malignant lesions.
It showed only one false negative case: a patient with DCIS
who was not identified with galactography. Although this
patient has been classified as negative both on galactography







Figure 5: 41-year-old patient with persistent bloody discharge of the right breast: craniocaudal (a) andmediolateral oblique (b) galactographic
projections show a ductal ectasia condition with wall duct focal irregularities.MRI images (T1-weighted 3D flash), acquired on the axial plane,





Figure 6: 54-year-old patient, presenting with bloody nipple discharge from the left breast: craniocaudal galactographic image (a) shows
ductal ectasia and filling defect, as observed in papillomatosis. (b) MRI images (T1-weighted 3D flash), acquired on the axial plane, show a
branched inhomogeneous ductal enhancement, suspicious of ductal malignant pathology. Histology revealed DCIS. This case represents a
galactography FN case; MRI correctly identified the malignant disease.
and on MRI, surgery was performed because of a persistent
discharge after one month follow-up and of a positive
cytology showing epithelial cells. Wenkel et al. [22] found the
same results; they had a DCIS case in a patient with bloody
nipple discharge not identified on MRI. Our patient had a
very small (7mm), low-grade DCIS, which was not showed
at MRI.
Nonetheless, our study has several limitations. The first
one is due to its retrospective design. Patients were selected
because of a specific symptom with a high possibility to have
pathology (benign or malignant); in fact, the majority of
them (45/53) had disease. This caused for both methods a
high specificity value. In addition, we had a restricted sample,
because we excluded a large number of patients with nipple
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discharge who did not perform galactography for nipple
retraction or intermittent discharge. Furthermore, the follow-
up period was limited: in patients who did not undergo
biopsy or surgery, the mean follow-up was only of 18 months.
An optimal follow-up should be at least three years to assess
the actual imaging examination false-negative rate.
5. Conclusions
Cancer represents a significant risk to patients having suspi-
cious bloody/serous-bloody discharge. Even if ductography
represents the standard imaging technique for these patients
evaluation, it is not always available and the possibility to
differentiate between benign and malignant lesions may be
controversial. Our findings suggest that MRI is able to dif-
ferentiate between the nipple discharge causes and according
to the reported literature, it shows a high sensitivity value
in detecting the ductal disease. Therefore, nipple discharge
should be considered a valid indication to perform MRI.
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